AIM: Tacrolimus is an immunosuppressant used in transplantation. This article reports the validation of the authors' recently developed genetics-based tacrolimus equation that predicts troughs. METHODS: Validation was performed in an independent cohort of 795 kidney transplant recipients receiving tacrolimus. The performance of the equation to predict initial troughs was assessed by calculating the bias and precision of the equation. For all troughs in the first 6 months post-transplant, a comparison was made between the troughs predicted using the equation versus those predicted using a basic apparent clearance model with no covariates. RESULTS: For initial troughs, the equation had a low bias (0.2 ng/ml) and high precision (1.8 ng/ml). For all troughs, the equation predicted troughs significantly better than the basic apparent clearance model. CONCLUSION: The tacrolimus equation had good bias and precision in predicting initial troughs and performed better than a basic apparent clearance model for all the troughs.
AIM: Tacrolimus is an immunosuppressant used in transplantation. This article reports the validation of the authors' recently developed genetics-based tacrolimus equation that predicts troughs. METHODS: Validation was performed in an independent cohort of 795 kidney transplant recipients receiving tacrolimus. The performance of the equation to predict initial troughs was assessed by calculating the bias and precision of the equation. For all troughs in the first 6 months post-transplant, a comparison was made between the troughs predicted using the equation versus those predicted using a basic apparent clearance model with no covariates. RESULTS: For initial troughs, the equation had a low bias (0.2 ng/ml) and high precision (1.8 ng/ml). For all troughs, the equation predicted troughs significantly better than the basic apparent clearance model. CONCLUSION: The tacrolimus equation had good bias and precision in predicting initial troughs and performed better than a basic apparent clearance model for all the troughs.
Authors: K Zucker; A Rosen; A Tsaroucha; L de Faria; D Roth; G Ciancio; V Esquenazi; G Burke; A Tzakis; J Miller Journal: Transpl Immunol Date: 1997-09 Impact factor: 1.708
Authors: Elizabeth A Sconce; Tayyaba I Khan; Hilary A Wynne; Peter Avery; Louise Monkhouse; Barry P King; Peter Wood; Patrick Kesteven; Ann K Daly; Farhad Kamali Journal: Blood Date: 2005-06-09 Impact factor: 22.113
Authors: H Tada; N Tsuchiya; S Satoh; H Kagaya; Z Li; K Sato; M Miura; T Suzuki; T Kato; T Habuchi Journal: Transplant Proc Date: 2005-05 Impact factor: 1.066
Authors: Lorraine D Ralph; Marie Sandstrom; Chris Twelves; Nicola A Dobbs; Alison H Thomson Journal: Br J Clin Pharmacol Date: 2006-07 Impact factor: 4.335
Authors: Jeffrey L Anderson; Benjamin D Horne; Scott M Stevens; Amanda S Grove; Stephanie Barton; Zachery P Nicholas; Samera F S Kahn; Heidi T May; Kent M Samuelson; Joseph B Muhlestein; John F Carlquist Journal: Circulation Date: 2007-11-07 Impact factor: 29.690
Authors: Rebecca A Pulk; David S Schladt; William S Oetting; Weihua Guan; Ajay K Israni; Arthur J Matas; Rory P Remmel; Pamala A Jacobson Journal: Pharmacogenomics Date: 2015-06-12 Impact factor: 2.533
Authors: W S Oetting; D P Schladt; W Guan; M B Miller; R P Remmel; C Dorr; K Sanghavi; R B Mannon; B Herrera; A J Matas; D R Salomon; P-Y Kwok; B J Keating; A K Israni; P A Jacobson Journal: Am J Transplant Date: 2015-10-20 Impact factor: 8.086
Authors: W S Oetting; B Wu; D P Schladt; W Guan; R P Remmel; R B Mannon; A J Matas; A K Israni; P A Jacobson Journal: Pharmacogenomics J Date: 2017-11-21 Impact factor: 3.550
Authors: Dennis A Hesselink; Rachida Bouamar; Laure Elens; Ron H N van Schaik; Teun van Gelder Journal: Clin Pharmacokinet Date: 2014-02 Impact factor: 6.447
Authors: K Sanghavi; R C Brundage; M B Miller; D P Schladt; A K Israni; W Guan; W S Oetting; R B Mannon; R P Remmel; A J Matas; P A Jacobson Journal: Pharmacogenomics J Date: 2015-12-15 Impact factor: 3.550